Kuros Biosciences AG
CSBTF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$952.16M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $952.16 Million |
|---|---|
| Enterprise Value | $955.31 Million |
| Earnings per Share | $0.06 |
| Beta | 0.76 |
| Outstanding Shares | 39,458,790 |
Return
| Return on Equity | 1.42% |
|---|---|
| Return on Assets | 0.85% |
| Return on Invested Capital | 9.72% |
Valuation & Multiples
| P/E Ratio | 112.15 |
|---|---|
| PEG | -41.2 |
| Price to Sales | 4.0 |
| Price to Book Ratio | 24.0 |
| Enterprise Value to Revenue | 3.88 |
| Enterprise Value to EBIT | 116.6 |
| Enterprise Value to Net Income | 932 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.15 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$91.00 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 3, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$111.60 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Kuros Biosciences AG
178 employees
CEO: Christopher T. Fair
Kuros Biosciences AG operates as a biopharmaceutical firm, concentrating on the commercialization and advancement of products designed for tissue repair and bone regeneration. Its operations span the United States, the European Union, an...